Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Business / Helus Pharma to present at H.C. Wainwright
Business conference participation

Helus Pharma to present at H.C. Wainwright

Analysis based on 8 articles · First reported Jun 01, 2026 · Last updated Jun 11, 2026

Sentiment
10
Attention
2
Articles
8
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The participation of Lewis Pharmacy in the H.C. Wainwright & Co. 7th Annual Neuro Perspectives Hybrid Conference could positively impact its stock price by increasing visibility and investor confidence in its novel serotonergic agonists (NSAs) pipeline. The event provides a platform for Lewis Pharmacy to highlight its clinical progress, including HLP003's Breakthrough Therapy Designation, which may attract new investors and strengthen existing shareholder sentiment.

pharmaceuticals biotechnology
Event Summary

Lewis Pharmacy, a clinical-stage pharmaceutical company, announced that its Chief Medical Officer, Amir Inamdar, will participate in a fireside chat at the H.C. Wainwright & Co. 7th Annual Neuro Perspectives Hybrid Conference on June 15-16, 2026. The company, operating as the commercial name of Cybin Inc., is developing novel serotonergic agonists (NSAs) for mental health conditions like major depressive disorder and generalized anxiety disorder. Its proprietary NSA, HLP003, has received Breakthrough Therapy Designation from the United States — Food and Drug Administration and is in Phase 3 clinical development. This conference participation aims to showcase Lewis Pharmacy's progress and research portfolio.

Key Actions
100 Lewis Pharmacy announced participation
90 Amir Inamdar will participate
70 United States — Food and Drug Administration granted designation Lewis Pharmacy
Entities Involved
priv
Lewis Pharmacy
Lewis Pharmacy is participating in the H.C. Wainwright & Co. 7th Annual Neuro Perspectives Hybrid Conference, which provides a platform to showcase its novel serotonergic agonists (NSAs) and clinical development progress, potentially increasing investor interest and visibility.
Importance 100 Sentiment 10
per
Amir Inamdar
Amir Inamdar, as Chief Medical Officer of Lewis Pharmacy, will represent the company in a fireside chat at the conference, highlighting the company's scientific and clinical expertise.
Importance 80 Sentiment 10
priv
H.C. Wainwright & Co.
H.C. Wainwright & Co. is hosting the 7th Annual Neuro Perspectives Hybrid Conference, providing the venue for Lewis Pharmacy's participation.
Importance 40 Sentiment 0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration granted Breakthrough Therapy Designation to Lewis Pharmacy's HLP003, a significant regulatory milestone mentioned in the context of the company's development.
Importance 30 Sentiment 0
stock
Cybin Inc.
Cybin Inc. is the parent company of Lewis Pharmacy, which operates as its commercial name. This event indirectly reflects on Cybin Inc.'s overall portfolio.
Importance 20 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.